Literature DB >> 8237802

Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation.

L M Rodriguez1, J L Smeets, B Xie, C de Chillou, E Cheriex, F Pieters, J Metzger, K den Dulk, H J Wellens.   

Abstract

Left ventricular (LV) function was studied in 30 patients with lone atrial fibrillation (AF) (paroxysmal [n = 27] and persistent [n = 3]) before and after ablation of atrioventricular conduction. In all patients, drug treatment did not control ventricular rate during AF or prevent recurrences of the arrhythmia, or both. LV ejection fraction, and LV end-systolic and end-diastolic, and left atrial dimensions were measured by echocardiography before (mean 7 +/- 10 months, range < 1 to 37) and after (14 +/- 20 months, < 1 to 77) ablation. Before ablation, LV ejection fraction was < or = 50% in 12 patients (group I) and > 50% in 18 (group II). After ablation, LV ejection fraction increased significantly in group I from 43 +/- 8% to 54 +/- 7% (p < 0.0001). There were also significant decreases in LV-end systolic and end-diastolic, and left atrial dimensions. No changes in these parameters were observed in group II. Groups I and II had a significant difference in the duration of AF (group I: mean 11 years, range 8 to 28; and group II: 5 years, 2 to 14) (p < 0.05). No difference was present in age, sex, New York Heart Association functional class for dyspnea, or type of ablation procedure. Thus, some patients with lone AF may show deterioration of LV function, which appears to be related to the duration of the arrhythmia; in these cases, LV function may improve significantly after ventricular rate control is accomplished by ablation of atrioventricular conduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8237802     DOI: 10.1016/0002-9149(93)90982-i

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

Review 1.  Endocavitary treatment of atrial fibrillation.

Authors:  S B Olsson; E I Hertervig; O Kongstad; C Meurling; S Yuan
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 2.  Transthoracic and transesophageal echocardiography in atrial fibrillation.

Authors:  C Stöllberger
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

4.  Atrial Fibrillation.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-08

5.  [Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

Authors:  P Kirchhof; A Goette; G Hindricks; S Hohnloser; K-H Kuck; T Meinertz; U Ravens; G Steinbeck; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

Review 6.  Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors:  Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

7.  Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation.

Authors:  M Edner; K Caidahl; L Bergfeldt; B Darpö; N Edvardsson; M Rosenqvist
Journal:  Br Heart J       Date:  1995-09

Review 8.  Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.

Authors:  Giuseppe Boriani; Mauro Biffi; Igor Diemberger; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Atrioventricular Nodal Catheter Ablation in Atrial Fibrillation Complicating Congestive Heart Failure.

Authors:  Osmar Antonio Centurión; Karina Elizabeth Scavenius; Laura B García; Luis Miño; Judith Torales; Orlando Sequeira
Journal:  J Atr Fibrillation       Date:  2018-06-30

Review 10.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.